Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Malignant melanoma.
de Braud F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N. de Braud F, et al. Among authors: bruzzi p. Crit Rev Oncol Hematol. 2003 Jul;47(1):35-63. doi: 10.1016/s1040-8428(02)00077-x. Crit Rev Oncol Hematol. 2003. PMID: 12853098 Review.
Bladder cancer.
de Braud F, Maffezzini M, Vitale V, Bruzzi P, Gatta G, Hendry WF, Sternberg CN. de Braud F, et al. Among authors: bruzzi p. Crit Rev Oncol Hematol. 2002 Jan;41(1):89-106. doi: 10.1016/s1040-8428(01)00128-7. Crit Rev Oncol Hematol. 2002. PMID: 11796234 Review.
Major and minor salivary glands tumours.
Licitra L, Grandi C, Prott FJ, Schornagel JH, Bruzzi P, Molinari R. Licitra L, et al. Among authors: bruzzi p. Crit Rev Oncol Hematol. 2003 Feb;45(2):215-25. doi: 10.1016/s1040-8428(02)00005-7. Crit Rev Oncol Hematol. 2003. PMID: 12604131 Review.
Cancer of the nasopharynx.
Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazzé S, Bruzzi P, Gatta G, Molinari R. Licitra L, et al. Among authors: bruzzi p. Crit Rev Oncol Hematol. 2003 Feb;45(2):199-213. doi: 10.1016/s1040-8428(01)00210-4. Crit Rev Oncol Hematol. 2003. PMID: 12604130 Review.
Cancer of the oropharynx.
Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P, Lefebvre JL. Licitra L, et al. Among authors: bruzzi p. Crit Rev Oncol Hematol. 2002 Jan;41(1):107-22. doi: 10.1016/s1040-8428(01)00129-9. Crit Rev Oncol Hematol. 2002. PMID: 11796235 Review.
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C. Gregorc V, et al. Among authors: bruzzi p. J Clin Oncol. 2010 May 20;28(15):2604-11. doi: 10.1200/JCO.2009.27.3649. Epub 2010 Apr 20. J Clin Oncol. 2010. PMID: 20406925 Clinical Trial.
Anticancer innovative therapy congress: Highlights from the 10th anniversary edition.
De Santis F, Fucà G, Schadendorf D, Mantovani A, Magnani L, Lisanti M, Pettitt S, Bellone M, Del Sal G, Minucci S, Eggermont A, Bruzzi P, Bicciato S, Conte P, Noberini R, Hiscott J, De Braud F, Del Vecchio M, Di Nicola M. De Santis F, et al. Among authors: bruzzi p. Cytokine Growth Factor Rev. 2021 Jun;59:1-8. doi: 10.1016/j.cytogfr.2021.02.001. Epub 2021 Feb 14. Cytokine Growth Factor Rev. 2021. PMID: 33610464 Review.
Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700).
Merlano MC, Denaro N, Vecchio S, Licitra L, Curcio P, Benasso M, Bagicalupo A, Numico G, Russi E, Corvo' R, Bruzzi P; INTERCEPTOR trialists. Merlano MC, et al. Among authors: bruzzi p. Oncology. 2020;98(11):763-770. doi: 10.1159/000507733. Epub 2020 Jul 6. Oncology. 2020. PMID: 32629446 Free article. Clinical Trial.
394 results